Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30121657 | 1.00 | MAOB (0.59) | MAOBCYP3A4TP53MAOATSHR | |
| SCHEMBL13338101 | 0.86 | MAOB (0.59) | MAOBMAOATSHRALDH1A1ACHE | |
| SCHEMBL28890994 | 0.84 | MAOB (0.48) | MAOBCYP3A4TP53MAOATSHR | |
| SCHEMBL31691312 | 0.81 | ALDH1A1 (0.65) | MAOBCYP3A4MAOATSHRALDH1A1 | |
| SCHEMBL20530603 | 0.81 | MAOB (0.58) | MAOBCYP3A4MAOAACHECA12 | |
| SCHEMBL3054840 | 0.81 | CYP3A4 (0.58) | MAOBCYP3A4TP53MAOATSHR | |
| SCHEMBL30085021 | 0.81 | CYP3A4 (0.58) | MAOBCYP3A4TP53MAOATSHR | |
| SCHEMBL513677 | 0.81 | CYP3A4 (0.58) | MAOBCYP3A4TP53MAOATSHR | |
| SCHEMBL30772215 | 0.79 | CYP3A4 (0.61) | MAOBCYP3A4TP53TSHRAPP | |
| SCHEMBL20530611 | 0.79 | MAOB (0.54) | MAOBCYP3A4MAOAALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111116950-B | High-performance polyimide film and preparation method thereof | 株洲时代华鑫新材料技术有限公司 | 2022-08-23 | — | — | CN | claimed |
| CN-111187436-A | High-performance colorless transparent polyimide film and preparation method thereof | 株洲时代华鑫新材料技术有限公司 | 2020-05-22 | — | — | CN | claimed |
| CN-111116950-A | High-performance polyimide film and preparation method thereof | 株洲时代华鑫新材料技术有限公司 | 2020-05-08 | — | — | CN | claimed |
| EP-1303567-B2 | VOLUME-MODIFIED CASTING COMPOUNDS BASED ON POLYMERIC MATRIX RESINS | ABB RESEARCH LTD (CH) | 2007-09-05 | — | — | EP | claimed |
| EP-1303567-B1 | VOLUME-MODIFIED CASTING COMPOUNDS BASED ON POLYMERIC MATRIX RESINS | ABB RESEARCH LTD (CH) | 2004-12-08 | — | — | EP | claimed |
| US-12297157-B2 | 18F-labeled peptide ligands useful in PET and Cerenkov luminescene imaging | CORNELL UNIVERSITY (US) | 2025-05-13 | — | — | US | disclosed |
| US-20240425473-A2 | ENZYME INHIBITORS AND VIRAL INFECTION THERAPY | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-12-26 | — | — | US | disclosed |
| US-20240109859-A1 | ENZYME INHIBITORS AND VIRAL INFECTION THERAPY | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-04-04 | — | — | US | disclosed |
| US-20230339882-A1 | SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230339882-A1 | SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| EP-4249005-A2 | 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS | Cornell University (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3493856-B1 | 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS | UNIV CORNELL (US) | 2023-08-09 | — | — | EP | disclosed |
| WO-2009158571-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS AND USES THEREOF (US) | 2009-12-30 | — | — | WO | disclosed |
| CN-100554251-C | A kind of maleimide derivatives and preparation method thereof | CHINESE ACAD INST CHEMISTRY (CN) | 2009-10-28 | — | — | CN | disclosed |
| CN-1896058-A | Maleimide derivative and its preparation | CHINESE ACAD INST CHEMISTRY (CN) | 2007-01-17 | — | — | CN | disclosed |
| US-5631209-A | ALGICIDES | ROHM AND HAAS COMPANY (US) | 1997-05-20 | — | — | US | disclosed |
| US-5502027-A | ALGICIDES | ROHM AND HAAS COMPANY (US) | 1996-03-26 | — | — | US | disclosed |
| EP-0415642-B1 | Glutarimides | ROHM & HAAS (US) | 1995-12-06 | — | — | EP | disclosed |
| US-5393735-A | N-(halo-oxy-)phenyl substituted cyclic imides | ROHM AND HAAS COMPANY (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0415642-A1 | Glutarimides | ROHM AND HAAS COMPANY (US) | 1991-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297157-B2 | 18F-labeled peptide ligands useful in PET and Cerenkov luminescene imaging | VIP, CALCA, GLP1R | MAOB 3230/4885CYP3A4 4509/4885TP53 1809/4885 |
| US-20230339882-A1 | SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF | PTPRF, PTPRCAP, PTPRJ | MAOB 3515/4885CYP3A4 4659/4885TP53 508/4885 |
| US-20240109859-A1 | ENZYME INHIBITORS AND VIRAL INFECTION THERAPY | CTPS1, CTPS2, TYMS | MAOB 1371/4885CYP3A4 479/4885TP53 1299/4885 |
| US-20240425473-A2 | ENZYME INHIBITORS AND VIRAL INFECTION THERAPY | CTPS1, CTPS2, TYMS | MAOB 1371/4885CYP3A4 479/4885TP53 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.